Objective Elagolix is an oral, non-peptide, gonadotropin-releasing hormone antagonist.
Elagolix was evaluated in premenopausal women with heavy menstrual bleeding (HMB;> …

Objective To evaluate the safety and efficacy of elagolix vs. placebo and elagolix with low-
dose E 2/progestogen add-back therapy. Design Proof-of-concept, dose-ranging, multiple …

Objective: To evaluate the 6-month efficacy and safety of elagolix, an oral, non-peptide,
gonadotropin-releasing hormone antagonist, with/without add-back therapy, as compared to …

METHODS: This double-blind, randomized, placebo-controlled, parallel group study
evaluated the efficacy and safety of 6 months of treatment in 2 cohorts, with four arms/cohort …

METHODS: These were two replicate, investigational, double-blind, randomized, placebo-
controlled, 6-month, phase 3 studies (Elaris UF-1 and Elaris UF-2) where patients were …

Objective Evaluate safety and efficacy of elagolix (an oral GnRH antagonist) alone and
combined with low-dose estrogen+ progestin add-back therapy regimens in premenopausal …

Objective To evaluate the impact of elagolix, an oral gonadotropin-releasing hormone
antagonist, on the health-related quality of life (HRQL) in women with heavy menstrual …

Objective To investigate efficacy of elagolix plus add-back therapy (1 mg estradiol and 0.5
mg norethindrone acetate once daily) on patient-reported nonbleeding symptoms and …

ABSTRACT Introduction Uterine fibroids (UFs) are the most common benign tumor arising
from myometrium of reproductive age women, with significant financial burden estimated in …

METHODS: Women who received elagolix 300 mg twice-daily with add-back (estradiol 1
mg/norethindrone acetate 0.5 mg once-daily [E2/NETA]) or elagolix alone in the preceding …